NRx Pharmaceuticals intends to offer shares of its common stock in an underwritten public offering. The company plans to grant the underwriter a 30-day option to purchase an additional 15% of the shares sold. BTIG, LLC is serving as the lead bookrunner, with Lucid Capital Markets, LLC acting as joint bookrunning manager. Proceeds are intended for working capital and general corporate purposes to support growth.